PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,056 shares of the company’s stock after selling 164 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in PROCEPT BioRobotics were worth $661,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. KRS Capital Management LLC raised its holdings in PROCEPT BioRobotics by 0.5% in the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after acquiring an additional 225 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of PROCEPT BioRobotics during the third quarter worth $27,000. KBC Group NV raised its holdings in shares of PROCEPT BioRobotics by 32.6% during the third quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares during the period. Raleigh Capital Management Inc. acquired a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth $32,000. Finally, Blue Trust Inc. raised its holdings in shares of PROCEPT BioRobotics by 11.7% during the third quarter. Blue Trust Inc. now owns 4,441 shares of the company’s stock worth $356,000 after purchasing an additional 466 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at PROCEPT BioRobotics

In other news, EVP Alaleh Nouri sold 28,092 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at approximately $5,096,605.36. This trade represents a 34.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Reza Zadno sold 26,420 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $92.57, for a total transaction of $2,445,699.40. Following the transaction, the chief executive officer now owns 205,605 shares of the company’s stock, valued at approximately $19,032,854.85. This trade represents a 11.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 107,355 shares of company stock worth $10,327,788 in the last 90 days. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Stock Up 0.3 %

PRCT stock opened at $66.23 on Thursday. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a fifty-two week low of $45.20 and a fifty-two week high of $103.81. The firm’s 50-day simple moving average is $80.04 and its 200 day simple moving average is $79.56. The stock has a market cap of $3.46 billion, a PE ratio of -33.96 and a beta of 1.03.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PRCT shares. Wells Fargo & Company reissued an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Truist Financial reissued a “buy” rating and set a $105.00 target price (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a report on Monday, December 2nd. They set an “overweight” rating and a $105.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a “hold” rating and a $95.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).